Alteration of immune response using pan DR-binding peptides

Details Alteration of immune response using pan DR-binding peptides Alteration of immune response using pan DR-binding peptides

2007-04-10

2007-04-10

Chan, Christina (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023400

Reexamination Certificate

active

09709774

ABSTRACT:
The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

REFERENCES:
patent: 5114713 (1992-05-01), Sinigaglia
patent: 5196512 (1993-03-01), Bianchi et al.
patent: 5336758 (1994-08-01), Berzofsky et al.
patent: 5679640 (1997-10-01), Gaeta et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 5785973 (1998-07-01), Bixler et al.
patent: 0 534 615 (1993-03-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 93/05011 (1993-03-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 9958658 (1999-11-01), None
Goldsby, RA et al. Kuby Immunology: 4th Edition. [2000] Goldsby et al, eds. W.H. Freeman and Co., New York. p. 209.
Germain, RN. in Fundamental Immunology, Fourth Edition. [1999] WE Paul et al, eds. Lippincott-Raven, Philadelphia. pp. 287-340.
Alexander, et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides”;Immunityvol. 1, 751-761 (Dec. 1994).
Bartoloni, et al., “Immunogeicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide”;Vaccinevol. 13, No. 5, pp. 463-470 (1995).
Bixler, et al., “Synthetic Peptide Representing a T-cell Epitope of CRM197 Substitutes as Carrier Molecule in aHaemophilus influenzaeType B (Hib) Conjugate Vaccine”; Adv. Exp. Med. Biol. 251: 175-180, (1989).
Borras-Cuesta et al., “Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells,” Eur. J. Immunol. vol. 17:1213-1215 (1987).
Brett et al., “Fine Specificity of T Cell Recognition of the Same Peptide in Association With Different I-A Molecules,” Journal of Immunology, vol. 143 No. 3 771-779 (Aug. 1989).
Brown, et al., “Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1”; Nature, vol. 364, 33-39, (Jul. 1993).
Busch, et al., “Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces”; International Immunology, vol. 2, No. 5 443-451 (1990).
Chong, et al., “A Strategy for Rational Design of Fully Synthetic Glycopeptide Conjugate Vaccines”; Infection and Immunity, vol. 65, No. 12 4918-4925, (Dec. 1997).
Chu, et al., “Further Studies on the Immunogenicity ofHaemophilus influenzaeType b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates”; Infection and Immunity, vol. 40, No. 1, 245-256 (Apr. 1983).
Clarke et al., “Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein,” Nature, vol. 330, 381-384 (Nov. 1987).
DiGeorge et al., “Immune Responses of Seven Different ‘Promiscuous’ T-Cell Epitopes on Chimeric Peptide Vaccine Design,” Peptide Vaccines and Immunology, pp. 732-733, The Ohio State University, Columbus, OH 43210.
Fern et al., “Promiscuous Malaria Peptide Epitope Stimulates CD45Ra T Cells From Peripheral Blood of Nonexposed Donors,” Journal of Immunology, vol. 148:907-913 (1992).
Ferrari et al., “Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen,” J. Clin. Invest. vol. 88:214-222 pp. 168-170 (Jul. 1991).
Francis et al., “Non-Responsiveness to a Foot-and-Mouth Disease Virus Peptide Overcome by Addition of Foreign Helper T-Cell Determinants,” Nature, vol. 330 (Nov. 1987).
Franke, et al., “Pan DR binding sequence provides T-cell help for induction of protective antibodies againstPlasmodium yoeliisporozoites”; Vaccine, 17: 1201-1205 (1999).
Greenstein et al., “A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific for HIV pp120,” Journal of Immunology vol. 148:3970-3977 No. 12 (Jun. 1992).
Hervas-Stubbs, et al. “Overcoming class II-linked non-responsiveness to hepatitis B vaccine”;Vaccinevol. 12, No. 10, (1994) pp. 867-871.
Hill, et al., “Conformational and Structural characteristics of Peptides Binding to HLA-DR Molecules”; The Journal of Immunology, vol. 147, No. 1, 189-197 (Jul. 1991).
Ho et al., “Identification of Two Promiscuous T Cell Epitopes from Tetanus Toxin*,” Eur. J. Immunol. vol. 20:477-483 (1990).
Ishioka, et al. “MHC Interaction and T Cell Recognition of Carbohydrates and Glycopeptides”;The Journal of Immunologyvol. 148 No. 8, pp. 2446-2451 (Apr. 1992).
Ishioka, et al. “Major histocompatibility complex class II association and induction of T cell responses by carbohydrates and glycopeptides”;Springer Semin. Immunopathol. 15:293-302 (1993).
Kaumaya et al., “Immunogenicity and Antigenicity of a Promiscuous T-Cell Epitope and a Topographic B-Cell Determinant of the Protein Antigen LDH-C4,” Peptides Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium Jun. 16-21, 1991, Cambridge, Massachusetts, pp. 883-885.
Kaumaya et al., “A Universal HTLV-I Template Vaccine Incorporating Cytotoxic, Neutralizing and Promiscuous Epitope,” Peptides, Vaccines and Immunology, pp. 712-714 The Ohio State University, Columbus, OH 43210.
Krieger, et al., “Single Amino Acid Changes in DR and Antigen Define Residues Critical for Peptide-MHC Binding and T Cell Recognition”; The Journal of Immunology, vol. 146, No. 7, 2331-2340 (Apr. 1991).
Lett, et al., “Immunogenicity of Polysaccharides Conjugated to Peptides Containing T- and B-cell Epitopes”; Infection and Immunity vol. 62, No. 3, 785-792, (Mar. 1994).
Meister et al., “Two Novel T Cell Epitope Prediction Algorithms Based on MHC-Binding Motifs; Comparison of Predicted and Published Epitopes from Mycobacterium tuberculosis and HIV Protein Sequences,” Vaccine vol. 13(6):581-591 (1995).
Milich et al., “Antibody Production to the Nucleocapsid and Envelope of the Hepatitis B Virus Primed by a Single Synthetic T Cell Site” Nature vol. 329 pp. 547-549(Oct. 1987).
O'Sullivan et al., “Characterization of the Specificity of Peptide Binding To Four Dr Haplotypes,” Journal of Immunology vol. 145:1799-1808 (Sep. 1990).
O'Sullivan, et al., “Truncation Analysis of Several DR Binding Epitopes”; The Journal of Immunology, vol. 146, No. 4, 1240-1246 (Feb. 1991).
O'Sullivan et al., “On the Interaction of Promiscuous Antigenic Peptides with Different Dr Alleles,” Journal of Immunology vol. 147:2663-2669 (Oct. 1991).
Panina-Bordignon, et al., “University immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells*”; Eur. J. Immunol. 19: 2237-2242 (1989).
Partidos et al., “Prediction and Identification of a T Cell Epitope in the Fusion Protein of Measles Virus Immunodominant in Mice and Humans,” Journal of General Virology vol. 71:2099-2105 (1990).
Powell, et al., “Peptide Stability in Drug Development. II. Effect of Single Amino Acid Substitution and Glycosylation on Peptide Reactivity in Human Serum”; Pharmaceutical Research, vol. 10, No. 9, 1268-1273 (1993).
Roche, et al., “High-Affinity Binding of an Influenza Hemagglutinin-Derived Peptide to Purified HLA-DR”; The Journal of Immunology, vol. 144, No. 5, 1849-1856 (Mar. 1990).
Sinigaglia et al., “A Mal

Affiliated with

Also associated with

Rating

Alteration of immune response using pan DR-binding peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alteration of immune response using pan DR-binding peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of immune response using pan DR-binding peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3773805